The Genomic Landscape of Breast Cancer As a Therapeutic Roadmap

Overview

Journal Cancer Discov

Specialty Oncology

Date 2013 Jan 16

PMID 23319768

Citations 109

Authors

Matthew J Ellis

Charles M Perou

Affiliations

Soon will be listed here.

Abstract

The application of high-throughput techniques to profile DNA, RNA, and protein in breast cancer samples from hundreds of patients has profoundly increased our knowledge of the disease. The etiologic events that drive breast cancer are finally coming into focus and should be used to set priorities for clinical trials. In this Prospective, we summarize some of the headline conclusions from 6 recent breast cancer "omics profiling" articles in Nature, with an emphasis on the implications for systemic therapy.

Citing Articles

The treatment landscape of triple-negative breast cancer.

Hu Y, Wang C, Liang H, Li J, Yang Q Med Oncol. 2024; 41(10):236.

PMID: 39210220 DOI: 10.1007/s12032-024-02456-9.

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.

Suba Z Cancers (Basel). 2024; 16(8).

PMID: 38672654 PMC: 11049279. DOI: 10.3390/cancers16081573.

A Long Way to Go: A Scenario for Clinical Trials of PI3K Inhibitors in Treating Cancer.

Trigueiros B, Santos I, Pimenta F, Avila A Cancer Control. 2024; 31:10732748241238047.

PMID: 38494880 PMC: 10946074. DOI: 10.1177/10732748241238047.

Advances in Breast PET Instrumentation.

Krishnamoorthy S, Surti S PET Clin. 2023; 19(1):37-47.

PMID: 37949606 PMC: 10712960. DOI: 10.1016/j.cpet.2023.09.001.

The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer.

Xia L, Ma W, Afrashteh A, Sajadi M, Fakheri H, Valilo M Biochem Med (Zagreb). 2023; 33(3):030504.

PMID: 37841775 PMC: 10564154. DOI: 10.11613/BM.2023.030504.

References

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Leung B, Potter A . Mode of estrogen action on cell proliferative kinetics in CAMA-1 cells. I. Effect of serum and estrogen. Cancer Invest. 1987; 5(3):187-94. DOI: 10.3109/07357908709011735. View

Chia S, Bramwell V, Tu D, Shepherd L, Jiang S, Vickery T . A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012; 18(16):4465-72. PMC: 3743663. DOI: 10.1158/1078-0432.CCR-12-0286. View

Banerji S, Cibulskis K, Rangel-Escareno C, Brown K, Carter S, Frederick A . Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012; 486(7403):405-9. PMC: 4148686. DOI: 10.1038/nature11154. View

Vassilev L . MDM2 inhibitors for cancer therapy. Trends Mol Med. 2006; 13(1):23-31. DOI: 10.1016/j.molmed.2006.11.002. View

Shangary S, Qin D, McEachern D, Liu M, Miller R, Qiu S . Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008; 105(10):3933-8. PMC: 2268798. DOI: 10.1073/pnas.0708917105. View

Shangary S, Wang S . Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res. 2008; 14(17):5318-24. PMC: 2676446. DOI: 10.1158/1078-0432.CCR-07-5136. View

Stumpel D, Schneider P, Seslija L, Osaki H, Williams O, Pieters R . Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia. 2011; 26(4):682-92. DOI: 10.1038/leu.2011.278. View

10.

Nielsen T, Parker J, Leung S, Voduc D, Ebbert M, Vickery T . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16(21):5222-32. PMC: 2970720. DOI: 10.1158/1078-0432.CCR-10-1282. View

11.

Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia M . FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010; 70(5):2085-94. PMC: 2832818. DOI: 10.1158/0008-5472.CAN-09-3746. View

12.

Sherr C . Cancer cell cycles. Science. 1996; 274(5293):1672-7. DOI: 10.1126/science.274.5293.1672. View

13.

Leonard J, LaCasce A, Smith M, Noy A, Chirieac L, Rodig S . Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012; 119(20):4597-607. DOI: 10.1182/blood-2011-10-388298. View

14.

Crowder R, Phommaly C, Tao Y, Hoog J, Luo J, Perou C . PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009; 69(9):3955-62. PMC: 2811393. DOI: 10.1158/0008-5472.CAN-08-4450. View

15.

Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-44. DOI: 10.1016/S0140-6736(10)60892-6. View

16.

Roberts P, Bisi J, Strum J, Combest A, Darr D, Usary J . Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst. 2012; 104(6):476-87. PMC: 3309128. DOI: 10.1093/jnci/djs002. View

17.

Vaske C, Benz S, Sanborn J, Earl D, Szeto C, Zhu J . Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics. 2010; 26(12):i237-45. PMC: 2881367. DOI: 10.1093/bioinformatics/btq182. View

18.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

19.

Bond G, Hu W, Levine A . MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005; 5(1):3-8. DOI: 10.2174/1568009053332627. View

20.

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View